See also:

• Business: Biotechnology and Pharmaceuticals: Pharmaceuticals: Research and Development  (160)

• ARIAD Pharmaceuticals, Inc. - Develops drugs which block intracellular signal transduction pathways for treating solid tumors and hematologic malignancies. Includes kits available, technology overview and investor data from Cambridge, Massachusetts. (Nasdaq: ARIA)
• Arqule, Inc. - Promotes their activated checkpoint therapy platform. Headquartered in Woburn, Massachusetts. (Nasdaq: ARQL)
• Cytogen Corp. - Develops proprietary systems utilizing monoclonal antibodies for the targeted delivery of diagnostic and therapeutic substances in oncology. Includes information for investors, and healthcare professionals in the USA, from Princeton, New Jersey. (Nasdaq: CYTO)
• Dendreon Corp. - Discovers and develops immunologically based therapeutic anticancer products. Includes progress of clinical trials, and data for investors from company based in Seattle, Washington. (Nasdaq: DNDN)
• Draxis Health Inc. - Produces radiolabeled compounds for diagnostic and therapeutic use in nuclear medicine and oncology. Includes examples that distinguish infection from inflammation, a peptide based on fibrin, and overview of facilities in Kirkland, Québec. [English, French and Spanish]
• Exelixis, Inc. - Genomics-based discovery company focused on development of drugs, crop protection, and plant biotechnology. Overview of research, investor relations and contacts in California and Portland, Oregon. (Nasdaq: EXEL)
• Favrille, Inc. - Biopharmaceutical company focused on the research, development and commercialization of targeted immunotherapies for the treatment of cancer and other diseases of the immune system.
• Genaera Corp. - Develops drugs for asthma, cancer, cystic fibrosis and age-related macular degeneration. Includes overview of clinical trials, investor information and news from company in Plymouth Meeting, Pennsylvania. (Nasdaq: GENR)
• Heal Corporation - Details of projects using resistance related to polyunsaturated fatty acids and catalase in vitro, applied in vivo to trout model. Includes publications, charity status, facilities and contacts in Olympia, Washington.
• ImmunoGen, Inc. - Licenses tumor-activated prodrug technology, for development of small molecule anticancer agents, to optimise potency and toxicity. Manufacturing in Norwood, and headquarters in Cambridge, Massachusetts. (Nasdaq: IMGN)
• Onyx Pharmaceuticals, Inc. - Discovers and develops small molecule therapeutics based upon the genetics of human disease, with emphasis on cell growth inhibitors. Includes clinical pipeline, technology overview and investor relations at Richmond, California. (Nasdaq: ONXX)
• OSI Pharmaceuticals Inc. - Researches and develops diagnostics and anticancer therapy in humans and other diseases associated with control of cell growth. Laboratories in Oxford, Boulder and Farmingdale, headquartered in Melville, New York. (Nasdaq: OSIP)
• Panacea Pharmaceuticals, Inc. - Focused on utilizing functional genomics and proteomics to develop therapeutic agents and diagnostic tests for diseases with substantial unmet clinical need.
• Serenex, Inc. - Drug discovery and development through the commercialization of chemoproteomics, fractionation and mining, purine-binding, mechanism of action determination, and toxicity screening.
• Transmolecular, Inc. - Developing treatments in oncology. Includes overview of disease targets, technology, clinical trials, partnering opportunities and contacts for careers in Cambridge, Massachusetts.